Filing Details
- Accession Number:
- 0001104659-18-016433
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-09 21:31:49
- Reporting Period:
- 2018-03-07
- Accepted Time:
- 2018-03-09 21:31:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1264587 | Stemline Therapeutics Inc | STML | Pharmaceutical Preparations (2834) | 450522567 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1456864 | David Gionco | C/O Stemline Therapeutics, Inc. 750 Lexington Avenue, Eleventh Floor New York NY 10022 | Chief Accounting Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2018-03-07 | 1,413 | $16.56 | 152,275 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2018-03-08 | 37,592 | $0.00 | 189,867 | No | 4 | A | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | A | Direct |
Footnotes
- In connection with the vesting of 2,893 shares on March 6, 2018, a total of 1,413 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
- Reflects the weighted average sale price. The range of prices for such transaction is $16.35 to $16.83. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
- Of the 152,275 shares, 109,200 shares are restricted stock.
- The 37,592 restricted shares will vest in four equal installments as follows: 9,398 shares on March 8, 2019; 9,398 shares on March 8, 2020; 9,398 shares on March 8, 2021; and 9,398 shares on March 8, 2022.
- Of the 189,867 shares, 146,792 shares are restricted stock.